Search for:
kralbetz.com1xbit güncelTipobet365Anadolu Casino GirişMariobet GirişSupertotobet mobil girişBetistbahis.comSahabetTarafbetMatadorbethack forumBetturkeyXumabet GirişrestbetbetpasGonebetBetticketTrendbetistanbulbahisbetixirtwinplaymegaparifixbetzbahisalobetaspercasino1winorisbetbetkom
Prince Harry’s ‘intimate conversation’ felt more like watching a therapy session – and it cost us £17.99 each | UK News

It feels like we’ve just sat through one of Prince Harry’s therapy sessions.

More than that, we’ve all just paid £17.99 for the privilege, albeit with a free copy of Spare thrown in.

This was billed as an “intimate conversation” and that’s exactly what we got, over an hour of Prince Harry talking us through his personal trauma and healing.

This was not a conversation that threw hand grenades at the royal family, there was no mention of Prince William or Camilla.

Read more:
Sussexes told to ‘vacate’ Frogmore Cottage
South Park takes on Harry and Meghan

Nothing was said about the coronation and whether he’ll come, or how he feels about being evicted from Frogmore Cottage.

This was Harry discussing how he dealt with the trauma of personal loss, how therapy, nature, drugs and Meghan helped with his healing.

No major revelations, but we learnt how he was scared therapy might make him lose memories of his mother.

How he grew up with a sense of numbness when it came to his feelings. How he’s “lost a lot” moving to the US, but is “grateful” his children are growing up away from the institution he grew up within.

Copies of the newly released autobiography from the Duke of Sussex, titled Spare, on display at Waterstones Piccadilly, London, as it goes on sale to the public for the first time. Picture date: Tuesday January 10, 2023.

And once again, Harry draws a stark comparison between his parenting style “smothering them with love”, and that of his father.

The palace will have been braced for bombshells, and while Harry did a lot of talking, unlike his previous interviews, he did no damage.

No doubt there will be a sigh of relief from both the King and the Prince of Wales.

Click to subscribe to the Sky News Daily wherever you get your podcasts

What we do know is whenever Harry talks, people will listen.

He speaks from the heart and doesn’t hold back. His fans will have loved every minute of this conversation.

It’s unlikely to have changed the minds of his critics, but they probably won’t have spent the £17.99 to find out.

Gene therapy cuts risk of bleeding in haemophilia B patients, study finds | UK News

A new gene therapy can substantially cut the risk of bleeding in people with the rare condition haemophilia B, according to a new study.

Researchers found people who received a single injection of the gene therapy, called FLT180a, did not need to inject themselves every week with clotting factors – proteins that help control bleeding.

Haemophilia is a rare condition that impacts the blood’s ability to clot.

It is typically inherited and mainly affects men.

People with the condition lack clotting factors, which mix with blood cells called platelets to stop bleeding after cuts and injuries.

They can still suffer debilitating joint damage – a consequence of the condition – even with the weekly injections currently available.

Haemophilia A is caused by a lack of factor VIII and is more common, while haemophilia B is caused by a deficiency of factor IX.

In a new 26-week trial led by the Royal Free Hospital, University College London and biotechnology company Freeline Therapeutics, experts found that a single treatment with FLT180a led to sustained production of the protein from the liver in nine out of 10 patients with severe or moderately severe haemophilia.

Lead author Professor Pratima Chowdary, from UCL, said: “Removing the need for haemophilia patients to regularly inject themselves with the missing protein is an important step in improving their quality of life.

“The long-term follow-up study will monitor the patients for durability of expression and surveillance for late effects.”

Patients on the trial had to take immune suppressing drugs over several weeks to several months to keep their immune systems from rejecting the treatment.

While the therapy was generally well received, all patients experienced side effects.

One who received the highest FLT180a dose developed an abnormal blood clot.

Professor Amit Nathwani, who co-founded Freeline, a company focused on liver-directed gene therapies, said: “Gene therapy is still a young field that pushes the boundaries of science for people with severe genetic diseases.”

He said the trial, which was published in the New England Journal of Medicine, adds to “the growing body of evidence that gene therapy has the potential to free patients from the challenges of having to adhere to lifelong therapy or could provide treatment where none exists today”.